The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multiplex genomic profiling of non-small cell lung cancer patients enrolled in the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin (WJOG6611LTR).
Hiroshige Yoshioka
Honoraria - Taiho Pharmaceutical
Isamu Okamoto
Honoraria - Pfizer; Taiho Pharmaceutical
Research Funding - Pfizer
Kazuko Sakai
No relevant relationships to disclose
Satoshi Morita
Honoraria - Taiho Pharmaceutical
Hiroyasu Kaneda
No relevant relationships to disclose
Koji Takeda
No relevant relationships to disclose
Tomonori Hirashima
No relevant relationships to disclose
Yoshihito Kogure
No relevant relationships to disclose
Tatsuo Kimura
No relevant relationships to disclose
Toshiaki Takahashi
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Shinji Atagi
Honoraria - Taiho Pharmaceutical
Takashi Seto
Honoraria - Taiho Pharmaceutical
Toshiyuki Sawa
No relevant relationships to disclose
Masashi Yamamoto
Research Funding - Taiho Pharmaceutical
Miyako Satouchi
Honoraria - Taiho Pharmaceutical
Motoyasu Okuno
Research Funding - Taiho Pharmaceutical
Seisuke Nagase
No relevant relationships to disclose
Kazuhiko Nakagawa
No relevant relationships to disclose
Yoichi Nakanishi
No relevant relationships to disclose
Kazuto Nishio
Research Funding - Pfizer